UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Combined anti-fibrotic and anti-inflammatory properties of JAK-inhibitors on macrophages in vitro and in vivo: Perspectives for scleroderma-associated interstitial lung disease

Biochemical pharmacology, 2020-08, Vol.178, p.114103, Article 114103

2020

Volltextzugriff (PDF)

Fedratinib, a newly approved treatment for patients with myeloproliferative neoplasm-associated myelofibrosis

Leukemia, 2021-01, Vol.35 (1), p.1-17

2021

Volltextzugriff (PDF)

The molecular basis of JAK/STAT inhibition by SOCS1

Nature communications, 2018-04, Vol.9 (1), p.1558-14, Article 1558

2018

Volltextzugriff (PDF)

Heterodimeric JAK―STAT activation as a mechanism of persistence to JAK2 inhibitor therapy

Nature (London), 2012-09, Vol.489 (7414), p.155-159

2012

Volltextzugriff (PDF)

JAK inhibition as a therapeutic strategy for immune and inflammatory diseases

Nature reviews. Drug discovery, 2017-12, Vol.16 (12), p.843-862

2017

Volltextzugriff (PDF)

Upadacitinib Induction and Maintenance Therapy for Crohn’s Disease

The New England journal of medicine, 2023-05, Vol.388 (21), p.1966-1980

2023

Volltextzugriff (PDF)

Pharmacokinetics, Pharmacodynamics, and Proposed Dosing of the Oral JAK1 and JAK2 Inhibitor Baricitinib in Pediatric and Young Adult CANDLE and SAVI Patients

Clinical pharmacology and therapeutics, 2018-08, Vol.104 (2), p.364-373

2018

Volltextzugriff (PDF)

JAK inhibitors for asthma

Journal of allergy and clinical immunology, 2021-10, Vol.148 (4), p.953-963

2021

Volltextzugriff (PDF)

A Jak1/2 inhibitor, baricitinib, inhibits osteoclastogenesis by suppressing RANKL expression in osteoblasts in vitro

PloS one, 2017-07, Vol.12 (7), p.e0181126-e0181126

2017

Volltextzugriff (PDF)

Updated results of the placebo‐controlled, phase III JAKARTA trial of fedratinib in patients with intermediate‐2 or high‐risk myelofibrosis

British journal of haematology, 2021-10, Vol.195 (2), p.244-248

2021

Volltextzugriff (PDF)

Aggressive B-cell lymphomas in patients with myelofibrosis receiving JAK1/2 inhibitor therapy

Blood, 2018-08, Vol.132 (7), p.694-706

2018

Volltextzugriff (PDF)

Clinical efficacy of launched JAK inhibitors in rheumatoid arthritis

Rheumatology (Oxford, England), 2019-02, Vol.58 (Supplement_1), p.i17-i26

Taylor, Peter C

2019

Volltextzugriff (PDF)

Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double-blind, randomised controlled phase 3 trials

The Lancet (British edition), 2021-06, Vol.397 (10290), p.2151-2168

2021

Volltextzugriff (PDF)

Janus kinase inhibitors in dermatology: Part I. A comprehensive review

Journal of the American Academy of Dermatology, 2022-02, Vol.86 (2), p.406-413

2022

Volltextzugriff (PDF)

Pharmacologic blockade of JAK1/JAK2 reduces GvHD and preserves the graft-versus-leukemia effect

PloS one, 2014-10, Vol.9 (10), p.e109799-e109799

2014

Volltextzugriff (PDF)

JAK Kinase Inhibition Abrogates STAT3 Activation and Head and Neck Squamous Cell Carcinoma Tumor Growth

Neoplasia (New York, N.Y.), 2015-03, Vol.17 (3), p.256-264

2015

Volltextzugriff (PDF)

CYT387, a novel JAK2 inhibitor, induces hematologic responses and normalizes inflammatory cytokines in murine myeloproliferative neoplasms

Blood, 2010-06, Vol.115 (25), p.5232-5240

2010

Volltextzugriff (PDF)

Inhibition of cytokine signaling by ruxolitinib and implications for COVID-19 treatment

Clinical immunology (Orlando, Fla.), 2020-09, Vol.218, p.108517-108517, Article 108517

2020

Volltextzugriff (PDF)

Safety and efficacy of upadacitinib in combination with topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis (AD Up): results from a randomised, double-blind, placebo-controlled, phase 3 trial

The Lancet (British edition), 2021-06, Vol.397 (10290), p.2169-2181

2021

Volltextzugriff (PDF)

Molecular Pathways: JAK/STAT Pathway: Mutations, Inhibitors, and Resistance

Clinical cancer research, 2013-04, Vol.19 (8), p.1933-1940

2013

Volltextzugriff (PDF)

JAK Inhibitors: Treatment Efficacy and Safety Profile in Patients with Psoriasis

Journal of Immunology Research, 2014-01, Vol.2014 (2014), p.1-7

2014

Volltextzugriff (PDF)

Baricitinib, a drug with potential effect to prevent SARS-COV-2 from entering target cells and control cytokine storm induced by COVID-19

International immunopharmacology, 2020-09, Vol.86, p.106749-106749, Article 106749

2020

Volltextzugriff (PDF)

Neutrophils provide cellular communication between ileum and mesenteric lymph nodes at graft-versus-host disease onset

Blood, 2018-04, Vol.131 (16), p.1858-1869

2018

Volltextzugriff (PDF)

The oral Janus kinase/spleen tyrosine kinase inhibitor ASN002 demonstrates efficacy and improves associated systemic inflammation in patients with moderate‐to‐severe atopic dermatitis: results from a randomized double‐blind placebo‐controlled study

British journal of dermatology (1951), 2019-10, Vol.181 (4), p.733-742

2019

Volltextzugriff (PDF)

Safety of Janus Kinase Inhibitors in Patients With Inflammatory Bowel Diseases or Other Immune-mediated Diseases: A Systematic Review and Meta-Analysis

Gastroenterology (New York, N.Y. 1943), 2020-05, Vol.158 (6), p.1554-1573.e12

2020

Volltextzugriff (PDF)

1 – 25 von 23.577

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(21.976)
Mit Volltextzugriff
(20.894)

Publikationsform

5 weitere anzeigen...

Weniger anzeigen...

Sprache

15 weitere anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

Science & Technology
(20.173)
Life Sciences & Biomedicine
(16.008)
Humans
(12.363)
Animals
(7.191)
Signal Transduction
(5.415)
Janus Kinase 2
(4.886)
Male
(4.245)
Female
(4.023)
Mice
(3.952)
Janus Kinase
(3.825)
Janus Kinase 2 - Genetics
(3.600)
Kinases
(3.389)
Mutation
(3.347)
Physical Sciences
(3.130)
Hematology
(3.085)
Phosphorylation
(3.083)
Oncology
(3.076)
Janus Kinase 2 - Metabolism
(2.798)
Biochemistry & Molecular Biology
(2.743)
Cell Biology
(2.482)

15 weitere anzeigen...

Weniger anzeigen...

Kollektion

MEDLINE
(16.383)
EZB Electronic Journals Library
(12.051)
Ingenta.com
(10.360)
Journals@Ovid Ovid Full Text
(7.396)
IngentaConnect Journals
(4.688)
Elsevier ScienceDirect Journals Complete
(4.604)
Wiley Online Library
(3.672)
Publisher or Other Site
(3.642)
Elsevier Journal Backfiles on ScienceDirect (DFG Nationallizenzen)
(3.196)
Wiley Online Library
(2.924)
Springer Journals
(2.336)
Springer Nature - Connect here FIRST to enable access
(1.528)
SpringerLINK Contemporary (Konsortium Baden-Württemberg)
(1.403)
Nexis Uni
(1.110)
Taylor & Francis Journals Auto-Holdings Collection
(977)
Taylor & Francis
(895)
Oxford University Press Journals Current
(775)
Taylor & Francis Online
(660)
Oxford Journals 2020 Medicine
(415)
BMJ Journals
(295)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

Menü

Weitere Dienste

Einstellungen

Combined anti-fibrotic and anti-inflammatory properties of JAK-inhibitors on macrophages in vitro and in vivo: Perspectives for scleroderma-associated interstitial lung disease

Fedratinib, a newly approved treatment for patients with myeloproliferative neoplasm-associated myelofibrosis

The molecular basis of JAK/STAT inhibition by SOCS1

Heterodimeric JAK―STAT activation as a mechanism of persistence to JAK2 inhibitor therapy

JAK inhibition as a therapeutic strategy for immune and inflammatory diseases

Upadacitinib Induction and Maintenance Therapy for Crohn’s Disease

Pharmacokinetics, Pharmacodynamics, and Proposed Dosing of the Oral JAK1 and JAK2 Inhibitor Baricitinib in Pediatric and Young Adult CANDLE and SAVI Patients

JAK inhibitors for asthma

A Jak1/2 inhibitor, baricitinib, inhibits osteoclastogenesis by suppressing RANKL expression in osteoblasts in vitro

Updated results of the placebo‐controlled, phase III JAKARTA trial of fedratinib in patients with intermediate‐2 or high‐risk myelofibrosis

Aggressive B-cell lymphomas in patients with myelofibrosis receiving JAK1/2 inhibitor therapy

Clinical efficacy of launched JAK inhibitors in rheumatoid arthritis

Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double-blind, randomised controlled phase 3 trials

Janus kinase inhibitors in dermatology: Part I. A comprehensive review

Pharmacologic blockade of JAK1/JAK2 reduces GvHD and preserves the graft-versus-leukemia effect

JAK Kinase Inhibition Abrogates STAT3 Activation and Head and Neck Squamous Cell Carcinoma Tumor Growth

CYT387, a novel JAK2 inhibitor, induces hematologic responses and normalizes inflammatory cytokines in murine myeloproliferative neoplasms

Inhibition of cytokine signaling by ruxolitinib and implications for COVID-19 treatment

Safety and efficacy of upadacitinib in combination with topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis (AD Up): results from a randomised, double-blind, placebo-controlled, phase 3 trial

Molecular Pathways: JAK/STAT Pathway: Mutations, Inhibitors, and Resistance

JAK Inhibitors: Treatment Efficacy and Safety Profile in Patients with Psoriasis

Baricitinib, a drug with potential effect to prevent SARS-COV-2 from entering target cells and control cytokine storm induced by COVID-19

Neutrophils provide cellular communication between ileum and mesenteric lymph nodes at graft-versus-host disease onset

The oral Janus kinase/spleen tyrosine kinase inhibitor ASN002 demonstrates efficacy and improves associated systemic inflammation in patients with moderate‐to‐severe atopic dermatitis: results from a randomized double‐blind placebo‐controlled study

Safety of Janus Kinase Inhibitors in Patients With Inflammatory Bowel Diseases or Other Immune-mediated Diseases: A Systematic Review and Meta-Analysis

Suchergebnisse filtern